FDA orders suicidal action warning on epilepsy drugs

WASHINGTON (Reuters) - Makers of epilepsy drugs must add a warning that the medicines carry a risk of suicidal thoughts or actions, U.S. health officials said on Tuesday.

“The risk of suicidal thoughts or behavior was generally consistent among the eleven drugs analyzed and was observed in patients who were treated for epilepsy, psychiatric disorders, and other conditions,” the Food and Drug Administration said in a statement on its website.

Epilepsy drugs include Pfizer Inc’s Lyrica and Neurontin, GlaxoSmithKline PLC’s Lamictal and Johnson & Johnson’s Topamax.

(Reporting by Lisa Richwine; editing by Maureen Bavdek)

Source

--------------------------------------------------------------------------------------------
Related Posts:


WASHINGTON (Reuters) - U.S. regulators have approved Epix Pharmaceuticals Inc’s Vasovist imaging agent to help detect blood vessel problems, the U.S. Food and Drug Administration said on Wednesday. Epix, which announced the approval on Monday, has said the injectable product can help doctors better track the flow of blood seen in scans and find blockages or

Full Post: U.S. FDA says Epix’s Vasovist cleared for sale
--------------------------------------------------------------------------------------------

WASHINGTON (Reuters) - Data on Pfizer Inc’s smoking cessation drug Chantix continue to back the product’s safety, the company said on Wednesday after a watchdog group called for stronger warnings about risks. Based on all data including clinical trials, “we stand by the efficacy and safety profile of Chantix when used as directed, an important treatment

Full Post: Pfizer says data support quit-smoking drug’s safety
--------------------------------------------------------------------------------------------

WASHINGTON (Reuters) - A review of clinical trial data from four drugmakers shows no overall risk of heart problems in patients taking drugs to treat osteoporosis, the U.S. Food and Drug Administration said on Wednesday. The agency reviewed studies on Merck & Co’s Fosamax, Roche’s Boniva, Novartis AG’s Reclast and Procter and Gamble Co’s Actonel and

Full Post: Studies do not link heart risk to bone drugs: FDA
--------------------------------------------------------------------------------------------

By Ransdell Pierson NEW YORK (Reuters) - U.S. regulators on Tuesday said their review of clinical trials does not suggest Merck & Co’s Singulair asthma drug or similar medicines cause suicide or suicidal thought, although the data were inadequate to draw a firm conclusion. However, the U.S. Food and Drug Administration said it was continuing to review

Full Post: FDA says Singulair data do not suggest suicide link
--------------------------------------------------------------------------------------------

Neurontin is an effective drug for treating seizures linked with epilepsy for adults and also for children who are at least 12 years of age. It is also used against nerve pain associated with postherpetic neuralgia and also against nerve pains caused by herpes zoster. An anti-epileptic medication, Neurontin works by affecting the chemicals and nerves

Full Post: Neurontin is used for treating seizures associated with epilepsy

Site Navigation

Most Read

Search